 Home > Active Ingredient News > Blood System > FDA approves first oral drug for patients with recurrent or refractive large B-cell lymphoma: nuclear export inhibitor XPOVIO

FDA approves first oral drug for patients with recurrent or refractive large B-cell lymphoma: nuclear export inhibitor XPOVIO

 Last Update: 2020-07-13
 Source: Internet
 Author: User

Tags

cilostazol drug class

approved

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Karyopharm Therapeutics announced that the U.SFood and Drug AdministrationAdministration(
FDA) has approved the company's first-class oral nuclear export selective inhibitor XPOVIO (selinexor) for the treatment of recurrent or refractive diffuse large B cellslymphoma(DLBCL) adult patients, including patients with resinal lysatomoma DLBCL patients after at least two systemic treatmentsSharon Shacham, Chief Scientific Officer of Karyopharm, said: "Accelerated approval of oral XPOVIO is an important milestone for patients with limited choice of relapse or refractive DLBCLThe approval ofmarks XPOVIO becoming the first approved oral drug in previously treated DLBCL patients, and XPOVIO is the first approved single drug for this highly invasive lymphoma"
SADAL studies demonstrated that XPOVIO reached the primary endpoint of the total mitigation rate, with an ORR of 29%, including 18 (13%) total mitigation (CR) and 21 (16%) partial mitigation (PR)the main secondary endpoints include the median response duration (DOR) of the reactive patientIn the patients who responded, 56% were relieved at 3 months, 38% at 6 months and 15% at 12 months

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Gadusol Powder Gadusol76663-30-4

CAS No.: 76663-30-4

Industrial Grade

$1-1.01/G FOB

Food Additive Iron fumarate for Nutritional Iron Supplements

CAS No.: 141-01-5

Pharmacy Grade

$24-26/G FOB

Aminobenzoic Acid CAS 56-91-7

CAS No.: 56-91-7

Pharmaceutical Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.